Aspira Women’s Health to Announce Second Quarter 2022 Financial Results and Host Conference Call on Wednesday, August 10

Rhea-AI Summary

Aspira Women’s Health announced the upcoming release of its financial results for Q2 2022 on August 10, 2022, before market open. The company will also host a conference call at 8:30 am ET to discuss these results and provide a corporate update. Aspira focuses on innovative testing solutions and bio-analytical products aimed at improving gynecologic health outcomes, specifically in ovarian cancer risk assessment. Their OVA1plus combines FDA-cleared products to assess ovarian malignancy risk. More details are available on their website.

Positive

• Focus on innovative testing solutions for women's health.
• Upcoming financial results presentation may enhance investor confidence.

Negative

• None.

AUSTIN, Texas, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira”), a bio-analytical based women’s health company focused on gynecologic disease, today announced that the company will report its financial results for the second quarter ended June 30, 2022 before the market open on Wednesday, August 10, 2022. Management will also host a conference call with investors to discuss financial results and provide a corporate update at 8:30am Eastern Time. Details for the call are below:

Conference Call & Webcast Details
Date:	Wednesday, August 10
Time:	8:30am ET
Toll Free:	1-877-407-4018
International:	1-201-689-8471
Conference ID:	13730747
Webcast:	https://viavid.webcasts.com/starthere.jsp?ei=1556156&tp_key=c5bafc5645

About Aspira Women’s Health Inc.
Aspira Women’s Health Inc. is transforming women’s health with the discovery, development, and commercialization of innovative testing options and bio-analytical solutions that help physicians assess risk, optimize patient management, and improve gynecologic health outcomes for women. Aspira Women’s Health is particularly focused on closing the ethnic disparity gap in ovarian cancer risk assessment and developing solutions for pelvic diseases such as pelvic mass risk assessment and endometriosis. OVA1plus^TM combines our FDA-cleared products, OVA1^® and OVERA^®, to detect risk of ovarian malignancy in women with adnexal masses. Aspira GenetiX^TM testing offers both targeted and comprehensive genetic testing options with a gynecologic focus. With over 10 years of expertise in ovarian cancer risk assessment, Aspira Women’s Health is working to deliver a portfolio of pelvic mass products over a patient’s lifetime with our cutting-edge research. The next generation of products in development include OVAWatch^TM and EndoCheck^TM. To improve patient accessibility, Aspira Women’s Health has recently launched our Aspira Synergy^TM technology transfer platform to empower health systems, academics, regional labs, and physician group labs to conduct genetic and specialty tests in-house. Visit our website for more information at www.aspirawh.com.

Investor Relations Contact: 
Ashley R. Robinson  
LifeSci Advisors, LLC  
Tel: 617-430-7577 
Arr@lifesciadvisors.com 

FAQ

When will Aspira Women’s Health report its Q2 2022 financial results?

Aspira Women’s Health will report its Q2 2022 financial results on August 10, 2022.

What time is the conference call for Aspira's financial results?

The conference call for Aspira's financial results is scheduled for 8:30 am ET on August 10, 2022.

What are the key products offered by Aspira Women’s Health?

Aspira offers products like OVA1plus for ovarian malignancy risk assessment and Aspira GenetiX for genetic testing.

How can investors access the Aspira financial results webcast?

Investors can access the Aspira financial results webcast through the link provided in the press release.